Plasma Fractionation Market Report 2026

The plasma fractionation market size has grown rapidly in recent years. It will grow from $34.14 billion in 2025 to $37.63 billion in 2026 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to growth in demand for immunoglobulins, increased prevalence of hematological disorders, technological advancements in plasma fractionation, expansion of hospital and clinical infrastructure, rise in awareness about plasma-derived therapies.

The plasma fractionation market size is expected to see rapid growth in the next few years. It will grow to $55.85 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing adoption of precision medicine, integration of ai in plasma manufacturing, expansion of global biopharmaceutical collaborations, rising investments in plasma collection centers, development of novel plasma-derived therapies. Major trends in the forecast period include advanced plasma fractionation techniques, biopharmaceutical product diversification, enhanced quality control and regulatory compliance, expansion of contract manufacturing organizations (cmos/cdmos), supply chain optimization in plasma products.

The growing prevalence of chronic diseases is expected to drive the expansion of the plasma fractionation market in the coming years. Chronic diseases are conditions that persist for one year or longer and require continuous medical care, with common examples including heart disease, cancer, and diabetes. Treating patients with chronic conditions through access to plasma-derived products helps reduce morbidity, enhance quality of life, and offers a cost-effective therapeutic approach, thereby increasing demand for plasma fractionation. For instance, in March 2025, according to GOV.UK, a UK-based government organization, the prevalence of GP-recorded type 2 diabetes among adults aged 17 and above in England reached 7% in March 2024, rising from 6.8% in March 2023. Therefore, the increasing burden of chronic diseases across all age groups is expected to propel the growth of the plasma fractionation market.

Major companies operating in the market are adopting advanced technologies, such as high-tech facility processes, to convert donated human plasma into essential medicines while improving efficiency and safety. For instance, in March 2023, CSL Behring, a Germany-based company, inaugurated a new plasma fractionation facility valued at $470 million that incorporates state-of-the-art technology to enhance the efficiency and safety of plasma processing, resulting in higher-quality and more dependable medicines. By expanding the supply of these critical therapies, the facility supports the rising demand and helps ensure that a greater number of patients can access life-saving treatments. The use of advanced automation and self-cleaning systems minimizes contamination risks and improves overall hygienic conditions, thereby strengthening patient safety.

In May 2024, LFB, a France-based biopharmaceutical company, acquired Amber Plasma for an undisclosed amount. Through this acquisition, LFB seeks to strengthen its plasma collection network across Europe and expand its capacity to support the manufacturing of plasma-derived therapies. Amber Plasma is a Czech Republic-based company specializing in plasma collection.

Major companies operating in the plasma fractionation market are Baxter International Inc., Bio Products Laboratory Limited, Biotest AG, CSL Limited, Grifols S. A, ADMA Biologics Inc., Green Cross Corporation, Hualan Bioengineering Inc., Intas Pharmaceuticals Ltd., Japan Blood Products Organization, Kedrion S. P. A., Kamada Ltd., LFB Biomedicaments S. A. S, Octapharma AG, Sanquin Plasma Products B. V., Shanghai Raas Blood Products Co. Ltd., Takeda Pharmaceutical Company, Terumo BCT, China Biologic Products Holdings Inc., China National Biotec Group, Emergent BioSolutions Inc., Bharat Serum Vaccines Limited, Plasma Therapeutics, Prothya Biosolutions B. V., BioPharma Plasma LLC, BioLife Plasma Services LP.

North America was the largest region in the plasma fractionation market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma fractionation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the plasma fractionation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have introduced challenges for the plasma fractionation market by increasing import costs for raw plasma and specialized manufacturing equipment, affecting production efficiency. Segments such as immunoglobulins and coagulation factors are most impacted, particularly in regions like Europe and Asia-Pacific where plasma imports are significant. However, tariffs have also encouraged local production and investments in domestic plasma fractionation facilities, potentially fostering self-sufficiency and innovation within the market.

The plasma fractionation market research report is one of a series of new reports that provides plasma fractionation market statistics, including plasma fractionation industry global market size, regional shares, competitors with a plasma fractionation market share, detailed plasma fractionation market segments, market trends and opportunities, and any further data you may need to thrive in the plasma fractionation industry. This plasma fractionation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Plasma fractionation refers to a process that combines multiple manufacturing steps to separate crude plasma fractions, which are then sequentially and systematically refined into specific therapeutic products in an integrated manner.

The primary products in the plasma fractionation market include immunoglobulins, coagulation factors, albumin, and protease inhibitors. Immunoglobulins are used in the treatment of a broad range of conditions, such as primary and secondary immunodeficiencies, autoimmune disorders, and inflammatory diseases. Immunoglobulins (Ig), also known as antibodies, are glycoproteins produced by plasma cells that play a vital role in the immune system by identifying and neutralizing foreign substances, including pathogenic bacteria and viruses. These products are applied across areas such as immunology, hematology, neurology, critical care, hemato-oncology, and rheumatology, and are utilized by end users including hospitals and clinics, clinical research laboratories, and academic institutions.

The plasma fractionation market includes revenues earned by entities by combining manufacturing steps to isolate, in a sequential and integrated manner. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.